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Chronic oxidative stress and systemic inflammation contribute to the pathology of several
chronic diseases, one among which is chronic obstructive pulmonary disease (COPD). In addi-
tion, increased oxidative stress and inflammation have been observed to be negatively associ-
ated with telomere length (TL). Our aim was to investigate the TL in COPD patients in relation
to pulmonary and extrapulmonary disease severity. Furthermore, based on experimental
evidence suggesting the effects of oxidative stress on telomere shortening, we studied the
association of TL with the antioxidant enzyme superoxide dismutase (SOD). One hundred
and two COPD patients with moderate to severe COPD were studied and compared with 19
healthy age-matched controls. Patients were characterized by elevated levels of inflammatory
markers (CRP, sTNF-receptors) and lower SOD-activity than the controls (p< 0.001), irrespec-
tive of the SOD genotype. TL was negatively associated with age (p < 0.01) and was
significantly shorter in COPD patients than controls (p< 0.05). Within the patient group age-
adjusted TL variability could not be explained by lung function and smoking history but
a modest association was found with the percentage of fat mass (p< 0.05). These data provideedance analysis; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; DLco,
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Telomere shortening in COPD 231evidence for a relationship between a disturbed oxidant/antioxidant balance and telomere
shortening and indicate that preservation of fat mass may be protective in delaying telomere
shortening in COPD patients.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Chronic systemic oxidative stress plays a major role in the
pathophysiology of chronic obstructive pulmonary disease
(COPD).1 COPD is characterized by incompletely reversible
airflow obstruction associated with pulmonary inflamma-
tion in which monocytes and macrophages are the
predominant inflammatory cells.1 Tobacco smoking is the
main risk factor for COPD. However, for reasons that are
still poorly understood, only a small proportion of smokers
eventually develops COPD.2 Moreover, in COPD patients
oxidative stress, resulting from an imbalance between the
production of reactive oxygen species and the antioxidant
defense, has been implicated with disease progression and
complications such as cachexia.3 Wasting of fat free mass
and at later stages also of fat mass is a common systemic
impairment in COPD, adversely affecting functionality,
morbidity and prognosis.
In addition, several animal and in vitro models have
shown that chronic oxidative stress induces an accelerated
rate of telomere loss.4e6 Telomeres are nucleoprotein
structures at the end of chromosomes and consist of
4e15 kbp of the hexanucleotides 50-TTAGGG-30.6,7 Telo-
meres prevent chromosomal ends from being recognized as
double strand breaks and protect them from end to end
fusion and degradation.8 In somatic cells, telomeres
shorten with each cell division and cells are triggered into
replicative senescence once the telomeres shorten to
a critical length.9,10 Since telomere length (TL) in the
somatic cells determines the number of cell divisions, TL
has been proposed as a marker for biological age.
Since cell division appeared to account only partially for
the loss of telomeres seen in cells, it was suggested that
other mechanisms, in particular oxidative stress, might be
involved in accelerated telomere shortening.6,11,12 Recent
studies indeed have linked telomere shortening to various
chronic metabolic and inflammatory diseases such as
atherosclerosis, diabetes type I and inflammatory bowel
disease, conditions that are all characterized by systemic
oxidative stress.13e17 Animal studies and in vitro models
have shown that the antioxidant enzyme superoxide dis-
mutase (SOD) may protect telomeres from shortening.4,18
We therefore hypothesized that telomere shortening might
be accelerated in patients with COPD and serve as
a biomarker of disease progression, and more specifically of
the risk for muscle wasting.
The aim of this study was twofold. First, we wanted to
investigate the TL in COPD patients in relation to cachexia
and muscle wasting. Since experimental evidence sug-
gested that oxidative stress is an important determinant of
telomere shortening, our second aim was to study the
association of TL with the major antioxidant enzymes SOD
and catalase. For this purpose, we measured TL in the
leukocytes of 102 COPD patients and compared these to 19healthy, age-matched controls. TL was measured using
quantitative PCR.19 In addition, SOD and catalase activity
were determined as well as the V16A polymorphism in the
gene encoding MnSOD.
Subjects and methods
Study population
One hundred and two clinically stable COPD patients
classified IIeIV according to the Global Initiative for
Chronic Obstructive Lung Disease guidelines were consec-
utively recruited on admission to a pulmonary rehabilita-
tion center (CIRO, Horn, The Netherlands). Exclusion
criteria were the presence of diseases such as malignan-
cies, gastrointestinal or kidney abnormalities, metabolic
or endocrine diseases and inflammatory diseases such as
diabetes. Most patients were using medication to treat
symptoms of the disease, including anticholinergics, b2-
agonists, theophylline and inhaled- and oral corticoste-
roids. Written informed consent was obtained from all
participants, and the study was approved by the ethical
review board of the University Hospital Maastricht. Twenty
healthy Dutch volunteers, gender- and age-matched, were
recruited by an advertisement in a local newspaper.
Characteristics of the patients and healthy controls are
listed in Table 1. Part of the data used in this study has
been described elsewhere.20
Pulmonary function tests
All participants underwent flow volume tests including the
measurement of FEV1 with the highest value from at least
three properly performed measurements being used for
the analysis. Diffusion capacity for carbon monoxide
(DLco) was measured by using the single breath method
(Masterlab, Jaeger, Wu¨rzburg, Germany). The values
obtained were expressed as a percentage of the reference
value.21
Body composition
Body composition was estimated using single frequency
(50 kHz) bioelectrical impedance analysis (BIA; Xitron
Technologies, San Diego, CA, USA). Fat free mass (FFM) was
calculated using the disease-specific equation proposed by
Schols22 and the FFM of healthy controls was calculated
using the equations of Lukaski.23 FFM-index (FFMI) was
calculated as FFM divided by height2 (kg/m2). Patients were
classified as cachectic when their FFMI was lower than
16 kg/m2 for men and lower than 15 kg/m2 for women. Fat
mass (FM; kg) was estimated as the total body weight minus
FFM.
Table 1 Characteristics of COPD patients and healthy
controls.
COPD HC
Sex, M/F 71/31 15/5
Age, years 62.9 9.3 60.7 3.5
Packyears of smoking 36.3 23.1a 13.3 18.0b
Body composition
FFMI 16.5 2.2a 20.2 2.5b
FM, kg 16.7 6.6 16.4 7.5
BMI, kg/m2 22.3 3.8a 25.7 2.8b
Lung function
FEV1, % predicted 34.6 13.5a 105.4 16.1b
DLco, % predicted 49.2 19.9a 109.6 22.8b
Medication
Anticholinergics, % 76
b2-Agonists, % 86
Inhaled corticosteroids, % 81
Oral corticosteroids, % 30
Theophylline, % 37
Inflammation markers
C-reactive proteinc 3.5 (0.4, 75.6)a 1.82 (0.16, 7.09)b
sTNFR 1.02 0.38a 0.91 0.21b
Definition of abbreviations: HC: healthy controls; FEV1: forced
expiratory volume in 1 s; DLco: diffusing capacity for carbon
monoxide. Data are presented as mean SD and tested with
one-factor analysis of variance (ANOVA). Values not sharing
a common superscript letter (a, b) are significantly different at
p< 0.05.
c Values are the median (range) and tested with the Manne
Whitney test.
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Fasting venous blood samples (10 ml) were drawn into
ethylenediaminetetraacetic acid (EDTA)-containing tubes
(Becton Dickinson Vacutainer Systems, Plymouth, UK) in the
early morning (08.00e09.00 h). After centrifugation twice
at 1000 g for 10 min at 4 C within 2 h of collection,
plasma for CRP and white blood cells for DNA extraction
were stored at 70 C. Genomic DNA was extracted from
the white blood cells by a salting out procedure.24 The
remaining red blood cells were washed twice with PBS. The
hemolysates were diluted 10:1 with distilled water.
TL measurement
TL was determined by quantitative PCR as described by
Cawthon.19 From seven patients and one healthy subject, no
PCR results couldbeobtained, due topoorquality of theDNA.
Twomastermixeswere prepared, onewith telomere primers
and one with HBG primers (1x IQ SYBR Green Supermix from
BioRad, CA, USA). Sequences and concentrations of the
primers are shown in Table 2. Sample DNA was pipetted in
a 96-wells plate at a final concentration of 10 ng/ml. Twenty
microliters of the mastermix was added and the plate was
shortly centrifuged. Each sample was run in triplicate. For
the standard curve a reference DNA sample was diluted seri-
ally to produce three concentrations of 1.25, 5 and 10 ng/ml.Negative controls (MilliQþmastermix) and positive controls
were added for every run. The positive controls were
derived from two different Hela cell lines, one with rela-
tively short telomeres (Hela S3: 5.5 kb) and one with long
telomeres (Hela 229: 14e15 kb). Hela cell lines were kindly
provided by Prof. Alexander Bu¨rkle, University of Konstanz,
Germany. PCR was performed using a BioRad MyiQ iCycler
single color RT-PCR detection system using iQ SYBR Green
Supermix, containing iTaq Polymerase, dNTPs, SYBR Green I
and buffers (BioRad, CA, USA).
Superoxide dismutase (SOD) and catalase activity
Hemoglobin (Hb) concentration in the 1:10 hemolysates
was determined spectrophotometrically based on the cya-
nomethemoglobin method.
SOD-activity was determined according to the method of
Sun et al.25 This method is based on the generation of
superoxide radicals produced by xanthine and xanthine
oxidase, which react with nitro-blue tetrazolium (NBT) to
form NBT-diformazan. SOD was extracted in a chlor-
oform:ethanol mixture in the ratio of 0.15:0.25, shaken for
15 min and centrifuged at 2500 g for 5 min at 4 C and the
supernatant was used for the assay. The reaction mixture
was composed of 20 ml of the sample, 930 ml of the
substrate containing 0.5 mM xanthine (Sigma, St. Louis,
USA), 0.5 mM NBT (Sigma, St. Louis, USA) in buffer and
40 U/l of xanthine oxidase (Sigma, St. Louis, USA). One unit
of SOD was defined as the amount of enzyme necessary to
produce 50% inhibition in the NBT reduction rate. SOD-
activity was measured at 560 nm and expressed as units per
milligram of Hb.
Catalase activity was measured according to Aebi26 in
a reaction mixture containing 20 ml hemolysate in 100 mM
phosphate buffer (pH 7.4). The reaction was started by the
addition of H2O2 (Merck, Germany) at a final concentration
of 10 mM, and the rate was measured spectrophotometri-
cally at 240 nm (Perkin Elmer Lambda-series) for 1 min at
25 C. One unit of catalase activity was defined as the
amount of catalase absorbed in 1 min at 25 C. Catalase
activity was then calculated from the change in absorbance
and finally expressed as units per gram of Hb.
C-reactive protein (CRP)
CRP was assessed in duplicate by high-sensitivity particle-
enhanced immunonephelometry (N Hs CRP, Dade Behring).
Polymorphism selection
The DNA sequence and allele frequency were obtained from
the Cancer SNP 500 database (http://snp500cancer.nci.nih.
gov).
Genotyping of polymorphism
Genotyping was performed on the DNA of thewhite blood cells
of 84 COPD patients and 18 controls according to the validated
method for genotyping.27,28 PCR primers MnSOD: left
50-GGTGACGTTCAGGTTGTTCA-30; right 50-GGCTGTGCTTTC
TCGTCTTC-30.
Table 2 Primer sequences and concentrations.
Primer Sequence Concentration (nM)
Telomere 1 CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT 100
Telomere 2 GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT 900
HBG forward GCTTCTGACACAACTGTGTTCACTAGC 300
HBG reverse CACCAACTTCATCCACGTTCACC 700
Figure 1 Telomere length in white blood cells (A) and SOD-
activity (B) in red blood cells in healthy controls (HC), and
COPD patients (*p< 0.001; **p< 0.05). Significantly different
between the different groups based on Student’s t-test.
Results are expressed as mean SEM.
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cycler (Biometra, Go¨ttingen, Germany) in a 10 ml volume,
containing PCR buffer (Invitrogen, Breda, The Nether-
lands), 0.2 mmol/l deoxynucleotide triphosphates (Invi-
trogen), and 40 ng template DNA. The final concentration
of the primers was 0.1 mM/l. Afterwards, the PCR products
were incubated with 4 ml ExoSap-IT (Amersham, Roo-
sendaal, The Netherlands) for 55 min at 37 C to digest the
contaminating deoxynucleotide triphosphates and PCR
primers. Enzymes were deactivated at 72 C for 15 min.
Genotyping was done by single base extension (SBE) using
SNaPshot (Applied Biosystems, Nieuwerkerk a/d IJssel, The
Netherlands) as described previously.28 SBE primers were
designed using primer 3 and Netprimer software. The
primers were designed to bind immediately adjacent 50 to
the specific SNP. SBE primer: 50-CCTGGAGCCCAGA
TACCCCAAA-30. After SBE, the samples were incubated at
37 C for 1 h with 1 unit shrimp alkaline phosphatase
(Amersham) to degrade the unincorporated dideox-
ynucleotide triphosphates. Afterwards, the SBE products
were diluted and mixed with deionized formamide con-
taining Genescan 120 LIZ size standard and denatured at
95 C for 5 min. Subsequently, the samples were analyzed
on an ABI Prism 3100 Genetic Analyzer using the Genescan
analysis software.
Statistical analysis
Results are expressed as mean SD for all variables that
were normally distributed, and as median (range) when
not-normally distributed. Differences between COPD
patients and healthy controls were tested using Student’s
t-test for the independent samples and the ManneWhitney
U-test when not-normally distributed. Differences in the
distribution of the genotypes between groups were exam-
ined by using the c2 test. To study the determinants of TL in
COPD, a multiple regression analysis was conducted with TL
as the dependent variable and gender, age, CRP, smoking
history (in packyears), parameters of body composition and
SOD-activity as the independent variables. A difference
with p< 0.05 was considered statistically significant.
Statistical analyses were analyzed with SPSS for Windows
(version 13.0; SPSS Inc., Chicago, IL, USA).
Results
The general characteristics of the subjects are shown in
Table 1. COPD patients were characterized by lower values
for FEV1, DLco and FFMI (p< 0.001) than the control group.
COPD patients had shorter telomeres when compared to the
control group (p< 0.05; Fig. 1A). Age negatively correlatedwith TL in the patients (rZ 0.079, p< 0.05; Fig. 2) and in
controls (rZ 0.145, pZ 0.108; Fig. 2). No associations of
smoking history, lung function parameters, FFMI or CRP could
be found with TL. COPD patients had lower levels of SOD-
activity than healthy controls (p< 0.001; Fig. 1B). The
distribution of SOD genotypes among patients and healthy
controls is shown in Table 3. There was no significant asso-
ciation between SOD-activity and the SOD polymorphism,
neither in patients nor in the controls. Furthermore, we
found a correlation between SOD-activity and TL in the
complete study population (Fig. 3A), which was not depen-
dent on the SOD genotype. This association remained
statistically significant after controlling for age, gender,
disease state (patient or control), smoking history and CRP
(Table 4). Catalase activity was also measured and tended to
be lower in COPD patients, but no significant differences or
correlations were observed (data not shown).
Figure 2 Relationship between telomere length and age for
healthy controls and patients. Telomere length significantly
correlated with age in patients (rZ 0.079; p< 0.05) and in the
total study population (rZ 0.087; p< 0.01).
Table 3 Distribution of genotype of COPD patients and
controls.
COPD HC
n % n %
MnSOD Total 84 18
TT 25 29.8 4 22.2
TC 34 40.5 8 44.4
CC 25 29.8 6 33.3
Genotype T> C Effect of polymorphism:
Decreased enzyme activity/ less
efficient antioxidant defense
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gender, TL variability could not be explained by lung
function and smoking history, but a modest association was
found with the percentage of fat mass (rZ 0.25, p< 0.05;
Fig. 3B).
Discussion
This study presents three observations that warrant further
investigation in larger population studies. Patients with
moderate to severe COPD were characterized by shorter
telomeres of their leukocytes than healthy age-matched
controls, which previously was reported for other chronic
inflammatory diseases as well.13e17 In addition, we observed
that TL was positively associated with SOD-activity.
Furthermore, within the patient group fat mass-index (FMI)
and fat percentage were positively associated with TL.
In this study, TL in the leukocytes of COPD patients and
in healthy controls appeared not related to smoking expo-
sure, which is in contrast to the data presented by Morla
et al.,29 who observed an effect of cumulative smoking
exposure on TL in the lymphocytes of both healthy smokers
and COPD patients. Several factors may explain this
discrepancy, such as different white blood cell fractions
that were studied, the fact that Morla et al. included only
males in their study, and the relatively small population
sizes of both studies. The general conclusion, however, was
that chronic exposure to oxidative stress from cigarette
smoking significantly contributed to accelerated telomere
loss.29 In our study population, we observed decreased SOD-
activity and a slightly decreased catalase activity in COPDpatients when compared to the healthy controls, indicating
a reduced antioxidant defense in patients. Together with
the observation that TL in the leukocytes of COPD patients
was significantly shorter than TL in the leukocytes of
healthy, age-matched controls, these data indicate that
increased oxidative stress is contributing to the shortening
of telomeres. In addition, a positive correlation between
SOD-activity and TL was found for the entire study pop-
ulation, providing the first evidence that antioxidant
defense protects against telomere shortening in a human
population. Until now, this has only been observed in
animal models and in vitro studies.4,18
When COPD patients were analyzed as a separate group,
however, the association between SOD-activity and TL was
not as strong as found for the entire group. Moreover, in the
patient group FMI and fat percentage were positively
associated with TL, indicating that fat mass may have a role
in protecting telomeres from shortening in COPD patients.
Recently, Mizoue et al.30 reported that weight loss was
associated with increased markers of oxidative DNA
damage, which also indicated that preservation of body
mass may be protective against oxidative DNA damage.
Paradoxally, in normal adult populations shorter TLs and
telomere attrition were recently reported to be positively
associated with fat mass and insulin resistance.31,32 The
positive association found between fat mass and TL in COPD
patients in our study may point to a pleiotropic effect of fat
mass; a higher fat mass is associated with an increased risk
for diseases associated with metabolic derangements, but
in patients with a chronic inflammatory disease a higher fat
mass appears to be associated with better protection
against degenerative processes.
In COPD patients no association was found between the
FFMI and telomere shortening, which was a surprising
finding since a low FFMI was earlier found to be an inde-
pendent predictor of mortality in COPD.33 Previously, it was
observed that in athletes with exercise-associated fatigue,
the TL of skeletal muscle tissue was dramatically shortened
and the authors suggested that this might indicate an
exhaustion of the proliferative capacity of satellite cells.34
Loss of telomeres may affect the regenerative capacity of
skeletal muscle tissue and enhance muscle wasting. It
remains to be determined, however, whether TL in the
muscle tissue of COPD patients is reduced, and whether this
relates to muscle wasting.
It should be noted that this study has potential limita-
tions. The control group is rather small when compared to
Figure 3 Associations between telomere length and SOD-activity in healthy controls (rZ 0.048; pZ 0.368) and COPD patients
(rZ 0.018; pZ 121) (A) and between telomere length and fat mass in COPD patients (B). SOD-activity positively correlated with
telomere length in the complete study population after adjustment for age, gender, disease state (patient or control), smoking
history and CRP (rZ 0.049; p< 0.05). Fat mass positively correlated with telomere length in COPD patients after adjustment for
age and gender (rZ 0.25; p< 0.05).
Telomere shortening in COPD 235the number of COPD patients. Despite this limitation,
a difference in telomere length was observed between the
two groups. This may indicate that with a larger control
population these differences are likely to be more distinct.
Furthermore, we studied COPD patients that were entering
a rehabilitation programme. Although we corrected in our
analysis for disease severity (cachectic/non-cachectic),
there is a possibility that the findings can be different for
COPD patients outside the clinic, which tend to have milder
disease symptoms.
The data obtained in this study indicate a relationship
between a disturbed oxidant/antioxidant balance and TL
shortening in a human population. However, it still needs
to be determined whether shorter telomeres are a cause
or consequence of this disturbed balance. Future, longi-
tudinal studies are required to unravel the relationship
between chronic oxidative stress and telomere shortening
and the potential consequences for the pathophysiology of
COPD.Table 4 Regression model with telomere length as the
dependent variable.
Variables p value
Age 0.001
SOD-activity 0.012
Smoking (packyears) 0.151
Gender 0.198
Disease (patient/control) 0.054
C-reactive protein 0.472Competing interest
None declared.
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